505 8th Avenue S.W.
Calgary, AB T2P 1G2
Full Time Employees:
|Mr. J. Roderick Matheson||Exec. Chairman & CEO||150k||N/A||N/A|
|Dr. Mark Williams M.B.A., Ph.D.||Pres, Chief Science Officer & Director||150k||N/A||1972|
|Mr. Harpreet Nijjar C.M.A., CPA||Chief Financial Officer||37.57k||N/A||1988|
|Ms. Jacqueline Groot||Corp. Sec.||N/A||N/A||N/A|
Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.
Marvel Biosciences Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.